메뉴 건너뛰기




Volumn 123, Issue 7-8, 2011, Pages 235-240

Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in Austrian primary care;Wirksamkeit und Verträglichkeit von Sitagliptin bei Typ-2-Diabetikern mit inadäquater Blutzuckereinstellung unter Metformin-Monotherapie. Eine österreichweite prospektive Observationsstudie

Author keywords

A1C; Blood glucose; Oral antidiabetic combination therapy; Primary care; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN;

EID: 79955800997     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-011-1559-6     Document Type: Article
Times cited : (3)

References (16)
  • 1
    • 33744968835 scopus 로고    scopus 로고
    • Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: The National Health and Nutrition Examination Survey
    • HE Resnick GL Foster J Bardsley RE Ratner 2006 Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002. The National Health and Nutrition Examination Survey Diabetes Care 29 531 537 16505501 10.2337/diacare.29.03.06.dc05-1254 (Pubitemid 44115349)
    • (2006) Diabetes Care , vol.29 , Issue.3 , pp. 531-537
    • Resnick, H.E.1    Foster, G.L.2    Bardsley, J.3    Ratner, R.E.4
  • 2
    • 0036315193 scopus 로고    scopus 로고
    • Evaluation of risk factors for development of complications in Type II diabetes in Europe
    • ODE-2 Advisory Board. 12136408 10.1007/s00125-002-0874-x 1:CAS:528:DC%2BD38XltlOnt7g%3D
    • A Liebl M Mata E Eschwège ODE-2 Advisory Board 2002 Evaluation of risk factors for development of complications in Type II diabetes in Europe Diabetologia 45 S23 S28 12136408 10.1007/s00125-002-0874-x 1:CAS:528: DC%2BD38XltlOnt7g%3D
    • (2002) Diabetologia , vol.45
    • Liebl, A.1    Mata, M.2    Eschwège, E.3
  • 3
    • 3042714557 scopus 로고    scopus 로고
    • The burden of treatment failure in type 2 diabetes
    • DOI 10.2337/diacare.27.7.1535
    • JB Brown GA Nichols A Perry 2004 The burden of treatment failure in type 2 diabetes Diabetes Care 27 1535 1540 15220224 10.2337/diacare.27.7.1535 (Pubitemid 38857422)
    • (2004) Diabetes Care , vol.27 , Issue.7 , pp. 1535-1540
    • Brown, J.B.1    Nichols, G.A.2    Perry, A.3
  • 5
    • 43449100355 scopus 로고    scopus 로고
    • Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study
    • 18435671 10.1111/j.1463-1326.2008.00882.x
    • F Alvarez Guisasola S Tofé Povedano G Krishnarajah R Lyu P Mavros D Yin 2008 Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study Diabetes Obes Metab 10 Suppl 1 25 32 18435671 10.1111/j.1463-1326.2008.00882.x
    • (2008) Diabetes Obes Metab , vol.10 , Issue.SUPPL. 1 , pp. 25-32
    • Alvarez Guisasola, F.1    Tofé Povedano, S.2    Krishnarajah, G.3    Lyu, R.4    Mavros, P.5    Yin, D.6
  • 6
    • 34250636401 scopus 로고    scopus 로고
    • Antidiabetic medications in overweight/obese patients with type 2 diabetes: Drawbacks of current drugs and potential advantages of incretin-based treatment on body weight
    • DOI 10.1111/j.1742-1241.2007.01441.x
    • E Bonora 2007 Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight Int J Clin Pract Suppl 154 19 28 17593274 10.1111/j.1742-1241.2007.01441.x 1:CAS:528:DC%2BD2sXpvFSnt70%3D (Pubitemid 46934643)
    • (2007) International Journal of Clinical Practice , vol.61 , Issue.SUPPL. 154 , pp. 19-28
    • Bonora, E.1
  • 7
    • 79955800879 scopus 로고    scopus 로고
    • International Diabetes Federation Clinical Guidelines Task Force
    • International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. 2005. www.idf.org
    • (2005) Global Guideline for Type 2 Diabetes
  • 8
    • 63149173251 scopus 로고    scopus 로고
    • Standards of Medical Care in Diabetes - 2009
    • American Diabetes Association. 10.2337/dc09-S013
    • American Diabetes Association 2009 Standards of Medical Care in Diabetes - 2009 Diabetes Care 32 Suppl. 1 S13 S61 10.2337/dc09-S013
    • (2009) Diabetes Care , vol.32 , Issue.SUPPL. 1
  • 10
    • 33845998516 scopus 로고    scopus 로고
    • The role of gut hormones in glucose homeostasis
    • DOI 10.1172/JCI30076
    • DJ Drucker 2007 The role of gut hormones in glucose homeostasis J Clin Invest 117 24 32 17200703 10.1172/JCI30076 1:CAS:528:DC%2BD2sXmvV2rsw%3D%3D (Pubitemid 46048446)
    • (2007) Journal of Clinical Investigation , vol.117 , Issue.1 , pp. 24-32
    • Drucker, D.J.1
  • 11
    • 33845476757 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    • DOI 10.2337/dc06-0706
    • B Charbonnel A Karasik J Liu M Wu G Meininger Sitagliptin Study 020 Group 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 29 2638 2643 17130197 10.2337/dc06-0706 1:CAS:528:DC%2BD2sXhtVGhtQ%3D%3D (Pubitemid 44912191)
    • (2006) Diabetes Care , vol.29 , Issue.12 , pp. 2638-2643
    • Charbonnel, B.1    Karasik, A.2    Liu, J.3    Wu, M.4    Meininger, G.5
  • 13
    • 34249853401 scopus 로고    scopus 로고
    • Review of sitagliptin phosphate: A novel treatment for type 2 diabetes
    • DOI 10.2147/vhrm.2007.3.2.203
    • B Gallwitz 2007 Review of sitagliptin phosphate: a novel treatment for type 2 diabetes Vasc Health Risk Manag 3 203 210 17580730 10.2147/vhrm.2007.3.2. 203 1:CAS:528:DC%2BD2sXntFOmt74%3D (Pubitemid 46860709)
    • (2007) Vascular Health and Risk Management , vol.3 , Issue.2 , pp. 203-210
    • Gallwitz, B.1
  • 14
    • 79955870668 scopus 로고    scopus 로고
    • Treatment of type 2 diabetes mellitus (T2DM) with Sitagliptin - Efficacy and safety in a real-life setting
    • K Kusterer HJ Rümann C Hens 2009 Treatment of type 2 diabetes mellitus (T2DM) with Sitagliptin - efficacy and safety in a real-life setting Br J Clin Pharmacol 68 Suppl. 1 52
    • (2009) Br J Clin Pharmacol , vol.68 , Issue.SUPPL. 1 , pp. 52
    • Kusterer, K.1    Rümann, H.J.2    Hens, C.3
  • 15
    • 0037126526 scopus 로고    scopus 로고
    • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
    • (2002) Circulation , vol.106 , pp. 3143-421
  • 16
    • 65449133147 scopus 로고    scopus 로고
    • Metformin - The gold standard in type 2 diabetes: What does the evidence tell us?
    • 19385978 10.1111/j.1463-1326.2008.01031.x 1:CAS:528:DC%2BD1MXlvFOiur0%3D
    • E Bosi 2009 Metformin - the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 11 Suppl. 2 3 8 19385978 10.1111/j.1463-1326.2008.01031.x 1:CAS:528:DC%2BD1MXlvFOiur0%3D
    • (2009) Diabetes Obes Metab , vol.11 , Issue.SUPPL. 2 , pp. 3-8
    • Bosi, E.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.